Clinical Features and Molecular Epidemiology of CMY-Type β-Lactamase-Producing Escherichia coli
Background. Knowledge of the clinical features of infections caused by Escherichia coli strains that produce plasmid-mediated AmpC β-lactamase is limited. Of the several groups of plasmid-mediated AmpC β-lactamases, CMY-type β-lactamase is the most common in the United States. Methods. We prospectively identified patients infected or colonized with E. coli strains that produce CMYtype β-lactamase, and we collected clinical data over a 7-month period. A retrospective cohort study was performed to identify features associated with these cases. Patients with extended-spectrum β-lactamase-producing E. coli were used as a control group. Pulsed-field gel electrophoresis, plasmid analysis, and phylogenetic typing were performed. Results. Twenty-two patients with infection or colonization due to CMY-type β-lactamase-producing E. coli and 25 patients with infection or colonization due to extended-spectrum β-lactamase-producing E. coli were identified. The demographic characteristics of the patients were similar in both cohorts. Patients with CMY-type β-lactamase-producing E. coli were significantly more likely to have symptomatic infection than were patients with extended-spectrum β-lactamase-producing E. coli (P = . 028). The CMY-type β-lactamase was identified as CMY-2 or its variants. Ninety-four percent of the CMY-type β-lactamase-producing isolates belonged to E. coli phylogenetic groups B2 and D, which are associated with virulence. Many of the isolates shared similar plasmid profiles, whereas the pulsed-field gel electrophoresis profiles were diverse. Co-resistance to non-β-lactam antimicrobials was common. Conclusion. In Pittsburgh, Pennsylvania, CMY-type β-lactamase-producing E. coli strains are almost as common as extended-spectrum β-lactamase-producing E. coli strains, and they cause symptomatic infection in the majority of cases..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Clinical Infectious Diseases - 48(2009), 6, Seite 739-744 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sidjabat, Hanna E. [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
JST091919193 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | JST091919193 | ||
| 003 | DE-627 | ||
| 005 | 20230504210243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 151228s2009 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)JST091919193 | ||
| 035 | |a (JST)40309030 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.75 |2 bkl | ||
| 100 | 1 | |a Sidjabat, Hanna E. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Features and Molecular Epidemiology of CMY-Type β-Lactamase-Producing Escherichia coli |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background. Knowledge of the clinical features of infections caused by Escherichia coli strains that produce plasmid-mediated AmpC β-lactamase is limited. Of the several groups of plasmid-mediated AmpC β-lactamases, CMY-type β-lactamase is the most common in the United States. Methods. We prospectively identified patients infected or colonized with E. coli strains that produce CMYtype β-lactamase, and we collected clinical data over a 7-month period. A retrospective cohort study was performed to identify features associated with these cases. Patients with extended-spectrum β-lactamase-producing E. coli were used as a control group. Pulsed-field gel electrophoresis, plasmid analysis, and phylogenetic typing were performed. Results. Twenty-two patients with infection or colonization due to CMY-type β-lactamase-producing E. coli and 25 patients with infection or colonization due to extended-spectrum β-lactamase-producing E. coli were identified. The demographic characteristics of the patients were similar in both cohorts. Patients with CMY-type β-lactamase-producing E. coli were significantly more likely to have symptomatic infection than were patients with extended-spectrum β-lactamase-producing E. coli (P = . 028). The CMY-type β-lactamase was identified as CMY-2 or its variants. Ninety-four percent of the CMY-type β-lactamase-producing isolates belonged to E. coli phylogenetic groups B2 and D, which are associated with virulence. Many of the isolates shared similar plasmid profiles, whereas the pulsed-field gel electrophoresis profiles were diverse. Co-resistance to non-β-lactam antimicrobials was common. Conclusion. In Pittsburgh, Pennsylvania, CMY-type β-lactamase-producing E. coli strains are almost as common as extended-spectrum β-lactamase-producing E. coli strains, and they cause symptomatic infection in the majority of cases. | ||
| 540 | |a Copyright 2008 Infectious Diseases Society of America | ||
| 655 | 4 | |a research-article | |
| 700 | 1 | |a Paterson, David L. |e verfasserin |4 aut | |
| 700 | 1 | |a Qureshi, Zubair A. |e verfasserin |4 aut | |
| 700 | 1 | |a Adams-Haduch, Jennifer M. |e verfasserin |4 aut | |
| 700 | 1 | |a O'Keefe, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Pascual, Alvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Baño, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Doi, Yohei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i in |t Clinical Infectious Diseases |d Oxford University Press, 1992 |g 48(2009), 6, Seite 739-744 |w (DE-627)JST025522906 |x 15376591 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2009 |g number:6 |g pages:739-744 |
| 856 | 4 | 0 | |u https://www.jstor.org/stable/40309030 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_JST | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.75 |q ASE |
| 951 | |a AR | ||
| 952 | |d 48 |j 2009 |e 6 |h 739-744 | ||